Recent developments

at Tullis and our portfolio companies

News

Keeping you current on new and follow-on investments, portfolio product and service milestones, publications and events, management and board transitions, and other developments in Tullis funds.

January

23

TriSalus Life Sciences Announces Preliminary Q4 and Full Year Unaudited 2024 Financial Results

DENVER–(BUSINESS WIRE)–Jan. 23, 2025– TriSalus Life Sciences® Inc. (Nasdaq: TLSI), is announcing preliminary unaudited fourth quarter and...

9

TriSalus Life Sciences® Announces Publication of Pre-Clinical Data Demonstrating Improved Delivery of Embospheres® to Liver Tumors using Pressure-Enabled Drug Delivery™ (PEDD™) via the TriNav® Infusion System

DENVER–(BUSINESS WIRE)–Jan. 9, 2025– TriSalus Life Sciences®, Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), TriSalus Life Sciences seeks...

8

TriSalus Announces Leadership Changes

James Young Appointed Chief Financial Officer; Richard Marshak Appointed Chief Commercial Officer; Jodi Devlin...

14

TriSalus Reports Q3 2024 Financial Results and Provides Business Update

– Reported Q3 and nine-month revenues of $7.3 million and $21.2 million respectively, up 42% and 66% year-over-year...

11

TriSalus Life Sciences® Forms Strategic Partnership with Geo-Med, LLC to Expand Access of the TriNav® Infusion System to U.S. Veterans with Liver Cancer

DENVER–(BUSINESS WIRE)–Nov. 11, 2024– TriSalus Life Sciences® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology...

7

TriSalus Life Sciences Launches TriNav® LV Infusion System and TriGuide™ Guiding Catheters, Expanding Portfolio of PEDD™ Devices for Improved Tumor Treatment

DENVER–(BUSINESS WIRE)–Nov. 7, 2024– TriSalus Life Sciences® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), a leader...

31

TriSalus Life Sciences to Host Third Quarter 2024 Financial Results Conference Call

Call Scheduled for Thursday, November 14, 2024, at 9:00am ET DENVER–(BUSINESS WIRE)–Oct. 31, 2024– TriSalus Life Sciences® Inc.,...

26

TriSalus Life Sciences Announces Appointment of Riad Salem, M.D., to its Scientific Advisory Board

DENVER–(BUSINESS WIRE)–Sep. 26, 2024– TriSalus Life Sciences® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI),...

15

TriSalus Reports Q2 2024 Financial Results and Business Update

DENVER–(BUSINESS WIRE)–Aug. 15, 2024– TriSalus Life Sciences Inc., (Nasdaq: TLSI), an oncology company integrating novel...

3

TriSalus Life Sciences Highlights Clinical Data from Phase 1b PERIO-02 Trial, Studying Delivery of Nelitolimod via Pressure-Enabled Drug Delivery in Patients with Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma at 2024 ASCO Annual Meeting

– Hepatic arterial infusion (HAI) of nelitolimod has been well tolerated and associated with encouraging...

15

TriSalus Reports Q1 2024 Financial Results and Business Update

DENVER–(BUSINESS WIRE)–May 15, 2024– TriSalus Life Sciences Inc., (Nasdaq: TLSI), today announced its financial results...

7

TriSalus Life Sciences Appoints Liselotte Hyveled to its Board of Directors

Accomplished industry veteran brings deep strategic and operational expertise DENVER–(BUSINESS WIRE)–May 7, 2024– TriSalus Life...

Recent developments

News

January

23

TriSalus Life Sciences Announces Preliminary Q4 and Full Year Unaudited 2024 Financial Results

January

9

TriSalus Life Sciences® Announces Publication of Pre-Clinical Data Demonstrating Improved Delivery of Embospheres® to Liver Tumors using Pressure-Enabled Drug Delivery™ (PEDD™) via the TriNav® Infusion System

January

8

TriSalus Announces Leadership Changes

November

14

TriSalus Reports Q3 2024 Financial Results and Provides Business Update

November

11

TriSalus Life Sciences® Forms Strategic Partnership with Geo-Med, LLC to Expand Access of the TriNav® Infusion System to U.S. Veterans with Liver Cancer

November

7

TriSalus Life Sciences Launches TriNav® LV Infusion System and TriGuide™ Guiding Catheters, Expanding Portfolio of PEDD™ Devices for Improved Tumor Treatment

October

31

TriSalus Life Sciences to Host Third Quarter 2024 Financial Results Conference Call

September

26

TriSalus Life Sciences Announces Appointment of Riad Salem, M.D., to its Scientific Advisory Board

August

15

TriSalus Reports Q2 2024 Financial Results and Business Update

June

3

TriSalus Life Sciences Highlights Clinical Data from Phase 1b PERIO-02 Trial, Studying Delivery of Nelitolimod via Pressure-Enabled Drug Delivery in Patients with Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma at 2024 ASCO Annual Meeting

May

15

TriSalus Reports Q1 2024 Financial Results and Business Update

May

7

TriSalus Life Sciences Appoints Liselotte Hyveled to its Board of Directors